Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines
K. S. Kim, B. K. Yoon, I. J. Oh, Y. C. Kim, Y. S. Kwon, Y. I. Kim, S. C. Lim, J. H. Lim, J. P. Jeong, H. J. Ban, S. Y. Chi, C. M. Park (Gwangju, , Suncheon, Republic Of Korea)
Source: Annual Congress 2010 - Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Oral Presentation
Number: 368
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. S. Kim, B. K. Yoon, I. J. Oh, Y. C. Kim, Y. S. Kwon, Y. I. Kim, S. C. Lim, J. H. Lim, J. P. Jeong, H. J. Ban, S. Y. Chi, C. M. Park (Gwangju, , Suncheon, Republic Of Korea). Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines. Eur Respir J 2010; 36: Suppl. 54, 368
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: